Lupus Anticoagulant and Anticardiolipin Antibodies in Serum of Patients Treated With Risperidone
J Clin Psychiatry 2009;70(5):769-771 [letter]
© Copyright 2014 Physicians Postgraduate Press, Inc.
Access to this article is available to valid users
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Register: If you do not have one already, register for a free account.
Letter to the Editor
Sir: In recent years, several studies reported an increased
rate of cerebrovascular events in patients treated with risperidone.
In April 2005, the U.S. Food and Drug Administration issued
a health advisory warning concerning an increased risk of
death among patients with dementia who were treated with
atypical antipsychotic agents.
Risperidone is a second-generation antipsychotic agent that
reportedly increases the blood level of glucose and alters
changes in lipid profiles.